Skip to content

A Multi-Center Study on the Metoprolol Standard Dosing Pathway of Metoprolol Application in Chinese Patients with Acute Coronary Syndrome

A Multi-Center Study on the Metoprolol Standard Dosing Pathway of Metoprolol Application in Chinese Patients with Acute Coronary Syndrome

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014288
Enrollment
Unknown
Registered
2018-01-03
Start date
2018-01-05
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Case series:metoprolol

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged 18 years or above; 2) Hospitalized due to acute coronary syndrome; (The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischemia and includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA)). 3) Able and willing to provide written informed consent and to comply with the study.

Exclusion criteria

Exclusion criteria: 1) Cardiac shock; 2) Unstable heart failure; 3) Beta-agonist therapy on a continuous or intermittent basis; 4) Hypotension (BPII; 8) Suspected acute myocardial infarction with heart rate0.24 sec or systolic blood pressure <100mmHg; 9) Existing contraindication for metoprolol or allergic to metoprolol or any excipients; 10) Participation in another clinical study with an investigational product during the last 3 months; 11) Previous enrolment in the present study; 12) Subjects the investigator thinks not suitable for this study. E.g. cancer, increased risk of cardiogenic shock; 13) Inability to sign the informed consent form; 14) Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
The percentage of patients achieving target dose at time of discharge.;

Contacts

Public ContactYundai Chen

General Hospital of PLA

cyundai@vip.163.com+86 13311119778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026